|
|
|
|
| LEADER |
05909cam a2200529Mu 4500 |
| 001 |
on1119628105 |
| 003 |
OCoLC |
| 005 |
20210423014343.0 |
| 006 |
m o d |
| 007 |
cr |n|---||||| |
| 008 |
190914s2019 cau ok 000 0 eng d |
| 040 |
|
|
|a EBLCP
|b eng
|e pn
|c EBLCP
|d UKMGB
|d OCLCO
|d OCLCF
|d OCLCQ
|d OPELS
|d OCLCQ
|d N$T
|
| 015 |
|
|
|a GBB9F6576
|2 bnb
|
| 016 |
7 |
|
|a 019541134
|2 Uk
|
| 020 |
|
|
|a 0128178914
|
| 020 |
|
|
|a 9780128178911
|q (electronic bk.)
|
| 020 |
|
|
|z 9780128178904
|q (pbk.)
|
| 035 |
|
|
|a (OCoLC)1119628105
|
| 050 |
|
4 |
|a RS164
|
| 082 |
0 |
4 |
|a 615.19
|2 23
|
| 100 |
1 |
|
|a Egbuna, Chukwuebuka.
|
| 245 |
1 |
0 |
|a Phytochemicals As Lead Compounds for New Drug Discovery
|
| 260 |
|
|
|a San Diego :
|b Elsevier,
|c 2019.
|
| 300 |
|
|
|a 1 online resource (380 pages)
|
| 336 |
|
|
|a text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a computer
|b c
|2 rdamedia
|
| 338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
| 588 |
0 |
|
|a Print version record.
|
| 505 |
0 |
|
|a Front Cover; Phytochemicals as Lead Compounds for New Drug Discovery; Phytochemicals as Lead Compounds for New Drug Discovery; Copyright; Contents; List of contributors; I -- Plants as natural sources of drugs; 1 -- Plant secondary metabolites as lead compounds for the production of potent drugs; 1.1 Medicinal plants and phytochemicals; 1.1.1 Case Study 1: development of new analogues of combretastatins as tubulin inhibitors; 1.1.2 Case Study 2: development of coumarin analogues as antiretroviral agents; 1.1.3 Case Study 3: oseltamivir phosphate as an antiinfluenza drug; 1.2 Conclusion
|
| 504 |
|
|
|a References2-Factors affecting the choice for plant-based products in drug discoveries; 2.1 Introduction; 2.1.1 The process of drug discovery; 2.1.2 Efficacy of plant material; 2.1.3 Molecular size; 2.1.4 Stability of natural compounds; 2.1.5 Pharmacokinetics and pharmacodynamics; 2.1.6 Factors affecting the collection of plant samples; 2.1.7 Toxicity; 2.1.8 Ease of structural modification; 2.2 Conclusion; References; 3-Advances in computer-aided drug discovery; 3.1 Introduction; 3.1.1 Bioactive compounds as sources of drugs; 3.1.2 Chemical structure determination
|
| 505 |
8 |
|
|a 3.1.3 Reverse pharmacology3.1.4 Computer-aided drug discovery process; 3.1.4.1 Target identification; 3.1.4.1.1 Genomic techniques; 3.1.4.1.2 Forward and reverse genetics; 3.1.4.1.3 Proteomics; 3.1.4.2 Target validation; 3.1.4.3 Lead identification; 3.1.4.4 Lead optimization; 3.1.5 Structural considerations in drug discovery; 3.1.5.1 Affinity profiling; 3.1.5.2 Target specificity; 3.1.5.3 Quantitative structure-activity relationships; 3.1.5.3.1 1D-QSAR; 3.1.5.3.2 2D-QSAR; 3.1.5.3.3 3D-QSAR; 3.1.5.3.4 Multidimensional quantitative structure-activity relationship; 3.1.5.4 Molecular docking
|
| 505 |
8 |
|
|a 3.1.6 Bioinformatics and genomics3.1.6.1 Bioinformatics-overview; 3.1.6.2 Bioinformatics tools; 3.1.6.3 Writing language for software packages; 3.1.7 Implications of the human genome project on in silico drug discovery; 3.1.8 Current in silico analyses possible; 3.1.9 ADME-Tox; 3.1.10 Future possibilities; References; 4 -- FDA drug candidacy acceptance criteria and steps: problems and way forward; 4.1 Introduction; 4.1.1 Drug approval framework; 4.1.1.1 The clinical trials; 4.1.2 FDA acceptance of foreign clinical studies not conducted under an IND
|
| 505 |
8 |
|
|a 4.1.2.1 Acceptance of foreign clinical studies4.1.3 Regulatory approaches on botanical drug development (NDAs); 4.1.3.1 Challenges in developing global botanical drugs; 4.1.3.2 Development of novel botanical drugs using traditional medicinal plant sources; 4.1.3.3 Description and documentation of products; 4.1.3.4 Quality control; 4.1.3.4.1 Quality control systems; 4.1.3.4.2 Record and document control; 4.1.3.5 Botanical raw materials; 4.1.3.6 Safety tests on animals; 4.1.3.7 Placebo; 4.1.3.8 Labeling; 4.1.3.9 Nonclinical safety assessment; 4.1.3.9.1 Pharmacokinetic studies
|
| 500 |
|
|
|a 4.1.3.9.2 General toxicity studies
|
| 520 |
|
|
|a Phytochemicals as Lead Compounds for New Drug Discovery presents complete coverage of the recent advances in the discovery of phytochemicals from medicinal plants as models to the development of new drugs and chemical entities. Functional bioactive compounds of plant origin have been an invaluable source for many human therapeutic drugs and have played a major role in the treatment of diseases around the world. These compounds possess enormous structural and chemical diversity and have led to many important discoveries. This book presents fundament concepts and factors affecting the choice for plant-based products, as well as recent advances in computer-aided drug discovery and FDA drug candidacy acceptance criteria. It also details the various bioactive lead compounds and molecular targets for a range of life-threatening diseases including cancer, diabetes, and neurodegenerative diseases. Written by a global team of experts, Phytochemicals as Lead Compounds for New Drug Discovery is an ideal resource for drug developers, phytochemists, plant biochemists, food and medicinal chemists, nutritionists and toxicologists, chemical ecologists, taxonomists, analytical chemists, and other researchers in those fields. It will also be very valuable to professors, students, and researchers in this domain.
|
| 650 |
|
0 |
|a Drug development.
|
| 650 |
|
0 |
|a Phytochemicals.
|
| 650 |
|
7 |
|a Drug development.
|2 fast
|0 (OCoLC)fst00898670
|
| 650 |
|
7 |
|a Phytochemicals.
|2 fast
|0 (OCoLC)fst01063235
|
| 655 |
|
4 |
|a Electronic books.
|
| 700 |
1 |
|
|a Polgar, Timea.
|
| 700 |
1 |
|
|a Kumar, Shashank.
|
| 700 |
1 |
|
|a Ezzat, Shahira M.
|
| 700 |
1 |
|
|a Ifemeje, Jonathan C.
|
| 700 |
1 |
|
|a Kaliyaperumal, Saravanan.
|
| 776 |
0 |
8 |
|i Print version:
|a Egbuna, Chukwuebuka.
|t Phytochemicals As Lead Compounds for New Drug Discovery.
|d San Diego : Elsevier, ©2019
|z 9780128178904
|
| 856 |
4 |
0 |
|3 ScienceDirect
|u https://www.sciencedirect.com/science/book/9780128178904
|
